1096-03-3

Basic information

• Product Name: 4-anilino-1-benzylpiperidine-4-carboxamide
• Synonyms: 4-anilino-1-benzylpiperidine-4-carboxamide;1-Benzyl-4-(phenylamino)piperidine-4-carboxamide;4-(Phenylamino)-1-benzyl-4-piperidinecarboxamide;4-Anilino-1-benzyl-4-piperidinecarboxamide;NSC 73749;4-Piperidinecarboxamide,4-(phenylamino)-(phenylmethyl);4-(Phenylamino)-1-(phenylmethyl)-4-piperidinecarboxamide;1-(benzyl)-4-(phenylamino)isonipecotamide
• CAS NO: 1096-03-3
• Molecular Formula: C₁₉H₂₃N₃O
• Molecular Weight: 309.40542
• EINECS: 214-141-2
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1096-03-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 186.8-188.2 °C
• Boiling Point: 522.9°Cat760mmHg
• Flash Point: 270.1°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 4.95E-11mmHg at 25°C
• Refractive Index: 1.641
• PKA: 15.37±0.20(Predicted)
• CAS DataBase Reference: 4-anilino-1-benzylpiperidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-anilino-1-benzylpiperidine-4-carboxamide(1096-03-3)
• EPA Substance Registry System: 4-anilino-1-benzylpiperidine-4-carboxamide(1096-03-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1096-03-3(Hazardous Substances Data)

Usage

Description

4-anilino-1-benzylpiperidine-4-carboxamide is a white solid compound with a complex molecular structure. It is characterized by the presence of an anilino group attached to a benzyl-substituted piperidine ring, which is further connected to a carboxamide group. 4-anilino-1-benzylpiperidine-4-carboxamide is known for its potential applications in the pharmaceutical industry, particularly as a modulator of muscarinic receptors.

Uses

Used in Pharmaceutical Industry:
4-anilino-1-benzylpiperidine-4-carboxamide is used as a modulator of muscarinic receptors for the treatment of central nervous system (CNS) disorders. Its interaction with muscarinic receptors can help in managing various conditions related to the CNS, such as Alzheimer's disease, schizophrenia, and other cognitive impairments.
The compound's ability to modulate muscarinic receptors is attributed to its structural features, which allow it to selectively bind and influence the receptor's activity. This selective modulation can lead to improved therapeutic outcomes and reduced side effects compared to non-selective treatments.

InChI:InChI=1/C19H23N3O/c20-18(23)19(21-17-9-5-2-6-10-17)11-13-22(14-12-19)15-16-7-3-1-4-8-16/h1-10,21H,11-15H2,(H2,20,23)

Upstream product

• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 62-53-3 aniline 

Downstream Products

• 61085-60-7 methyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylate 
• 85098-64-2 1-benzyl-4-(phenylamino)piperidine-4-carboxylic acid 
• 61085-72-1 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-benzyl-4-piperidinecarboxylate 
• 72996-78-2 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-4-piperidinecarboxylate 
• 63260-82-2 ethyl 1-benzyl-4-phenylamino-4-piperidinecarboxylate 
• 138091-52-8 8-(tert-Butoxycarbonyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 265107-18-4 1-Phenyl-1,3,8-triaza-spiro[4.5]dec-2-en-4-one 
• 180386-35-0 2-(8-(tert-butoxycarbonyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl)acetic acid 
• 1027421-85-7 tert-butyl 3-(2-methoxy-2-oxo-ethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decane-8-carboxylate 
• 61086-04-2 4-(N-phenylamino)-1-phenylmethyl-4-piperidinylmethanol 
• 120022-21-1 4-(Acetoxymethyl)-4-acetanilidopiperidine 
• 119997-26-1 N-Benzyl-4-<<(trimethylsilyl)oxy>methyl>-4-anilinopiperidine 
• 119997-27-2 N-Benzyl-4-(acetoxymethyl)-4-anilinopiperidine 

Relevant articles and documents

Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents

The synthesis, evaluation, and molecular modeling of a series of 18F-labeled 4-anilidopiperidines with high affinities for the μ-opioid receptor (μ-OR) are reported. On the basis of the high brain uptake and selective retention in brain regions that contain a high concentration of the μ-OR, combined with a good metabolic stability, [ 18F]fluoro-pentyl carfentanil ([18F]4) and 2-(±)[18F]-fluoropropyl-sufentanil ([18F]6) were selected as the lead compounds for further evaluation. The binding affinity to the human μ-OR was 0.74 and 0.13 nM for [18F]4 and [ 18F]6, respectively. In vitro autoradiography of [18F] 4 and [18F] 6 on rat brain sections produced patterns in accordance with the known distribution of μ-OR expression. Structure-activity relationships of the fluorinated compounds are discussed with respect to the interaction with an activated-state model of the μ-OR. Taken together, the in vivo and in vitro data indicate that [18F] 4 and [18F] 6 hold promise for studying the μ-opioid receptor in humans by means of positron emission tomography.

OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIES

The disclosure provides, inter alia, opioid haptens, opioid hapten conjugates, opioid vaccines, methods of treating or preventing opioid use disorder, methods of treating opioid overdose, and methods of generating and/or isolating antibodies selective for opioids.

1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY

The present invention relates to a 1,3,8-triazaspiro compound of Formula (I), wherein A is -CH2, -SO2 -, -NH-CO-, -NH-CS- or -CO-; the dashed line represents a single or double bond; R1 is a substituent selected from (C1-C3) alkyl, phenyl, thienyl and cyclohexyl, said substituent being optionally substituted by halogen or (C1 -C3) alkyl; and R2 is a substituent selected from H, (C1-C3) alkyl, (C1-C3) alkoxy, -CF3 and halogen; and wherein, when the dashed line is a double bond, A is -CH2 - and R1 is phenyl, or a pharmaceutically acceptable salt thereof for use in the treatment of reperfusion injury diseases. The 1,3,8-triazaspiro compound of the invention is a selective inhibitor of the C subunit of the F1/Fo-ATP synthase complex and a modulator of the mitochondrial permeability transition pore activity in mammalian cells and tissues, in the treatment of reperfusion injury diseases.

Synthesis of Hindered α-Amino Carbonyls: Copper-Catalyzed Radical Addition with Nitroso Compounds

The synthesis of sterically hindered anilines has been a significant challenge in organic chemistry. Here we report a Cu-catalyzed radical addition with in situ-generated nitroso compounds to prepare sterically hindered amines directly from readily available materials. The transformation is conducted at room temperature, uses abundant copper salts, and is tolerant of a range of functional groups.